Jeff Huntsman

Stay Ahead with Neopharm Adapting to the BIOSECURE Act? Neopharm provides tailored CRO services and GMP compliance in North America to keep your biopharma operations secure and compliant. Stay ahead with our expert solutions. Learn more: https://hubs.li/Q02Sn3290 Sponsored by Neopharm Labs #Biopharma #Pharmaceuticals #Compliance #BIOSECUREAct #R&D #RegulatoryExcellence #SupplyChainSecurity #Neopharm

8

Meetings between pharma and managed care organizations are increasingly more focused on financial topics than clinical ones. https://ow.ly/WiaC50SmHWS MMIT’s Jonathan Cecire and Norstella's Dinesh Kannan Kabaleeswaran discuss what manufacturers can do to ensure their brand messaging resonates with payers. #PharmaIndustry #ManagedCare #PharmaMarketing

9

New Blog Post Alert! Our latest blog highlights how Prescient supported a mid-size, oncology-focused pharmaceutical company in transforming its evidence-generation capabilities. This post showcases how proactive, strategic planning can enable impactful evidence generation that drives real-world success. Read more: https://bit.ly/3YY7Tef #Biopharma #EvidenceGeneration #OrganizationalTransformation #Oncology

19

Many innovative ideas can become obscured when communicated, which was a significant challenge for Patient Blood Management #PBM as it was introduced to benefit those suffering from #anemia, in hopes of enabling surgery without the use of donated blood upon leaving the ER (Emergency Room). The PBM educational approach supports bloodless surgical procedures. To reduce this obscurity, we are simplifying the message and increasing awareness, benefiting #researchers, manufacturers, and healthcare practitioners. Most importantly, we are enhancing the patient experience and raising public awareness. We are confident that many global organizations, healthcare providers, and blood management surgical equipment manufacturers will support our efforts as we continue to be pioneers in building a bridge of engagement for public access, which will benefit this field of medicine. Remember our medical icons, just in case one day you need direction to the OR. #Bloodlines #BBTS #Blood #SABM

5

Register now: https://loom.ly/V7hvN_g Join experts from AssistRx and MMIT (Managed Markets Insight & Technology) on Dec. 3 at 1 p.m. ET to discover the strategies life sciences organizations can use to alleviate copay program disruptions in 2025. During the webinar, we’ll detail how the perfect blend of tech and talent can help address recent payer activity, including new payer utilization management strategies and the changing copay accumulator and maximizer landscape. Can’t make it live? Request a recording when you sign up to view on your schedule. #InformedAccess #ImprovedOutcomes

15

[Article] KOL Engagement Dynamics - Influence Levels by Phase In this part 1 of 3 on "Navigating KOL Engagement Dynamics", we present our first key insight from our KOL engagement strategy report. This article addresses how pharmaceutical companies engage with KOLs possessing specific levels of influence to support the activities of the pharmaceutical organization during particular times within a product development lifecycle. Read on here: https://lnkd.in/eWbfURSs #medicalaffairs #msl #msls #thoughtleader #pharmaceuticalindustry #healthcare

5

"The spotlight on HCP and HCO spend disclosure underscores a new era of mandatory transparency within the life sciences industry." - Chapter 1, co-authored by Brian Fittipaldi, Director of Operations, Aggregate Spend and Andy Parks, Vice President of Compliance, explores the intricacies of Sunshine Transparency and Aggregate Spend, offering essential strategies for life sciences manufacturers. Unlock the insights now and stay ahead in compliance.  https://bit.ly/3Lchsya

11

Using MMIT data, researchers found that Part D plans are more likely than employer-sponsored plans to prefer reference biologics to biosimilars. https://ow.ly/MGWi30sFTEf This will change with the full implementation of the IRA. Learn more in this Q&A with Harvard researcher Luca Maini.

5

The frequency of payer/pharma meetings has increased, but the duration has decreased in the past year. https://ow.ly/wqe150SmI7p MMIT's Jonathan Cecire and Norstella's Dinesh Kannan Kabaleeswaran look at what the latest trends tell us about how pharma companies can advocate for better formulary positioning for their products. #PharmaCompanies #PharmaInsights #Formularies

8

Read the NAVLIN Last Week in Review Now: https://ow.ly/I3pZ50Tufxi This week from NAVLIN by EVERSANA's “Last Week in Review,” recapping the latest regulatory changes, pricing & reimbursement updates, drug approvals and more from across the world. Policy: The Czech Republic’s Ministry of Health is set to discuss an amendment to the Public Health Insurance Act, potentially revising the rules for maximum pricing of medicinal products. #PolicyUpdate #PharmaPricing Pricing & Reimbursement: The HRSA has warned J&J about potential penalties if it continues its rebate system for Stelara and Xarelto under the 340B Drug Pricing Program. #DrugPricing #Reimbursement HTA: NICE has recommended Daiichi Sankyo’s Vanflyta for various treatment stages of newly diagnosed FLT3-ITD-positive AML in its final draft guidance. #HTA #Oncology Drug Approval: China’s NMPA announced the approval of 31 innovative drugs between January and August 2024. #DrugApproval #Innovation C&G Therapy: Belgium and the Netherlands will pursue separate reimbursement negotiations for CSL Behring’s Hemgenix after a joint assessment via the BeNeLuxA initiative. #GeneTherapy #Reimbursement Managed Entry Agreements: A survey across OECD and EU member countries reveals mixed feelings about sharing net pricing data for medicines. #ManagedEntry #PharmaEconomics Conferences: NAVLIN Daily is proud to be an official media partner for MDRP Summit 2024, happening September 23-25 in Chicago. #MDRP2024 #PharmaConference Other: The NMPA’s CDE has published its pilot work plan for the Patient-Centered Rare Disease Drug Development initiative (CARE Plan). #RareDiseases #DrugDevelopment And so much more... Click through to read more on each story and stay informed! 📖✨

11

Pharma companies have many market access tasks to complete in the year leading up to launch. MMIT’s Ryan Witherington and Carolyn Zele share six key areas to focus on: https://ow.ly/sXkh50TyVth

7

Faster FDA approval through Real-World Evidence? Absolutely! FDA is incorporating RWE into regulatory decisions, helping pharmaceutical companies streamline the approval process. Learn how RWE can benefit your product's journey. #FDAApproval #RWE #CommercialStrategy #FacetLifeSciences https://hubs.ly/Q02Vb54y0

5

With the DSCSA stabilization period ending on Nov. 27, compliance exceptions have become a top concern. Tereance Puryear, senior solution consultant at TraceLink, discusses what companies can do to better manage DSCSA exceptions at FutureLink Boston. #FutureLink24 #LifeSciences

70

1 Comment

Patient access barriers are shifting, along with regulations and changing payer strategies. Tomorrow, hear the results of our #MarketAccess survey as experts from MMIT and The Dedham Group discuss best practices for #pharma companies in this BioPharma Dive webinar: https://ow.ly/Bh1850RIZaM.

13

Explore a step-by-step plan to activate your HCP segments with personalized messaging in less than 3 weeks using decision heuristics science. Watch this Intellus Worldwide-sponsored webinar from Newristics to learn more! #hcpsegments #hcp #Pharmamarketing

7

For over three decades, major Patient Blood Management (#PBM) associations, #pharmaceutical companies, #manufacturers, and #bloodless surgery hospital programs have heavily marketed to doctors, believing their buy-in was essential. However, this approach may have overlooked broader areas of interest. In the past five years, we've shifted our focus to cultivating public interest in Patient Blood Management, becoming pioneers in this approach. This has proven immensely valuable, creating an engaged infrastructure between healthcare providers and patients, enhancing understanding and collaboration in this evolving field of medicine. To address emerging challenges such as patient experience, safety, communication, and language, we're excited to introduce our Collaborative Optimal Outcome Language (COOL) initiative. This program provides support and training for hospitals to adapt to changing trends, paradigm shifts, and the needs of this new healthcare culture. The engagement bridge we've constructed is now open for all stakeholders in PBM to have open public access as we work together in collaboration, exchange, and education of a new language in life.

19

4 Comments

Commercialization can be particularly difficult for smaller manufacturers. https://ow.ly/bAil50Ubm7z This case study details how one small biopharma company partnered with MMIT to track coverage and restrictions for its first commercial launch in the rare disease space. Access the case study at the link in this post. #Biopharma #RareDiseases #Pharmaceuticals #LifeSciences

4